<DOC>
	<DOCNO>NCT00916942</DOCNO>
	<brief_summary>This study open-label multi-center evaluate tolerability treatment NGX-4010 use pre-patch topical application topical anesthetic cream . This open-label study . No hypothesis test perform . Eligible subject PHN level pain intensity level deem appropriate open-label treatment NGX-4010 , judge Investigator . Painful area maximum 1000 cm2 pre-treated lidocaine ( 2.5 % ) /prilocaine ( 2.5 % ) cream 60 minute follow single , 60-minute application NGX-4010 . Subjects may chronic pain medication regimen , currently use topical pain medication affect area , non-steroidal anti-inflammatory drug , menthol , methyl salicylate , local anesthetic include Lidoderm® ( lidocaine patch 5 % ) , steroids capsaicin .</brief_summary>
	<brief_title>Study NGX-4010 With Use Open Label Lidocaine ( 2.5 % ) /Prilocaine ( 2.5 % ) Cream Treatment Postherpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Prilocaine</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>1 . Between 18 90 year age , inclusive . 2 . Be good health . 3 . Prior diagnosis PHN pain persist least 3 month follow shingle vesicle crust . 4 . Pain due PHN , opinion investigator , appropriate severity treatment NGX4010 . The subject complete least 3 NPRS score . 5 . Intact , unbroken skin painful area ( ) treat . 6 . Female subject childbearing potential must negative serum beta hCG pregnancy test , perform Screening Visit . 7 . All subject must willing use effective method birth control and/or refrain participate conception process study 30 day follow study termination . 8 . Be willing able comply protocol requirement duration study participation . ( Such requirement include , limited : attending study visit , refrain elective surgery extensive travel study participation . ) 9 . Subjects must sign informed consent form study approve IRB . 1 . Receipt NGX4010 open label blind study patch within 12 week Study Patch Application Visit ( Day 0 ) . 2 . Concomitant opioid medication , unless orally transdermally administer exceed total daily dose morphine 60 mg/day , equivalent . Parenteral opioid use exclude , regardless dose . 3 . Unavailability effective pain medication strategy subject , unwillingness use opioid analgesic study treatment , high tolerance opioids preclude ability relieve treatmentassociated discomfort oxycodone analgesic , judged Investigator . 4 . Active substance abuse history chronic substance abuse within past year , prior chronic substance abuse ( include alcoholism ) judge likely recur study period investigator . 5 . Recent use ( within 7 day precede Study Patch Application Visit [ Day 0 ] ) topically apply pain medication , nonsteroidal antiinflammatory drug , menthol , methyl salicylate , local anesthetic ( include Lidoderm® ) , steroid capsaicin product painful area . 6 . Current use within past 30 day investigational agent 7 . Patients treat class I ( tocainide mexiletine ) III antiarrhythmic drug . 8 . Significant pain etiology PHN , example , compressionrelated neuropathy ( e.g. , spinal stenosis ) , fibromyalgia arthritis . Subjects must significant ongoing pain cause ( ) may interfere judge PHN related pain . 9 . Neuropathic pain area locate face , hairline scalp , and/or proximity mucous membrane 10 . Patients congenital idiopathic methemoglobinemia 11 . Patients glucose6phosphate dehydrogenase deficiencies 12 . Uncontrolled ( systolic blood pressure ≥ 175 mmHg diastolic blood pressure ≥105 mmHg ) unstable hypertension 13 . Clinically significant cardiovascular disease define cerebrovascular accident , transient ischemic attack , myocardial infarction , unstable angina , stable angina , current arrhythmia , coronary artery disease , heart surgery include coronary artery bypass graft surgery percutaneous coronary angioplasty/stent placement , valvular heart disease within past 6 month 14 . Clinically significant abnormal ECG screening . 15 . Clinically significant abnormal lab screening . 16 . Significant ongoing untreated abnormality cardiac , renal , hepatic , pulmonary function . 17 . Active malignancy past history malignancy past 5 year ( history squamous cell carcinoma basal cell carcinoma skin exempt exclusion criterion except occurred area treatment ) . 18 . Any implanted medical device ( spinal cord stimulator , intrathecal pump peripheral nerve stimulator ) treatment neuropathic pain . 19 . Hypersensitivity capsaicin ( i.e. , chili pepper OvertheCounter ( OTC ) capsaicin product ) , component capsaicin patch , Cleansing Gel , oxycodone , hydrocodone , adhesive . 20 . Patients known history sensitivity local anesthetic ( include lidocaine prilocaine ) amide type component product 21 . Evidence cognitive impairment include dementia may interfere subject 's ability complete daily pain diary require recall average pain level past 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Tolerability study</keyword>
</DOC>